LeonaBio’s SEC filings document the company’s transition from Athira Pharma, including the corporate name change, amended charter and bylaws, Nasdaq ticker change, and continuing public-company reporting on The Nasdaq Capital Market. Form 8-K reports cover operating and financial results, Regulation FD disclosures, material agreements, and the completed acquisition of rights related to the lasofoxifene development program.
Registration statements and proxy materials describe securities offered or issuable, pre-funded warrants and other warrant exercises, shareholder voting matters under Nasdaq rules, and capital-structure limits. The filings also disclose governance, risk factors, product-candidate development, and the historical Athira pipeline, including ATH-1105 and HGF-system small-molecule programs.
LeonaBio, Inc. reported that its Chief Financial Officer, Robert Renninger, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
According to the grant terms, these options vest in equal monthly installments over 48 months from the grant date, contingent on Mr. Renninger continuing to serve as a service provider under LeonaBio's 2026 Equity Incentive Plan. Following this award, he holds 300,000 stock options directly.
LeonaBio, Inc. reported that President and CEO Mark James Litton received a grant of stock options for 750,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.
These options were awarded as a compensation grant and will vest in equal monthly installments over 48 months, as long as he continues to serve as a Service Provider under LeonaBio’s 2026 Equity Incentive Plan. Following this award, he holds options covering 750,000 shares.
LeonaBio, Inc. is registering 58,464,567 shares of common stock for resale by the selling stockholders, to be offered from time to time by the holders identified under “Principal and Selling Stockholders.” The company is not selling any shares hereunder and will receive no proceeds from secondary sales.
LeonaBio would receive cash proceeds only if selling holders exercise certain warrants: cash exercise of 8,816,684 pre-funded warrants at $0.001 would yield approximately $8,816, and cash exercise of up to 23,031,494 warrants at $6.35 would yield approximately $146,249,987. Sales are subject to the PIPE warrants’ exercise limitations and beneficial ownership caps described in the prospectus.
LeonaBio, Inc. registers 5,502,402 shares of common stock for resale by the selling stockholder—shares issuable upon exercise of a pre-funded warrant. The prospectus states the company will receive proceeds only if the pre-funded warrant is exercised for cash at $0.001 per share, which would yield approximately $5,502.
The pre-funded warrant was issued to Sermonix Pharmaceuticals, Inc. as partial consideration for a license agreement and is subject to a 4.99% beneficial ownership limit and other exercise restrictions; stockholder approval for issuance upon exercise was obtained on March 18, 2026.
LeonaBio, Inc. is registering up to 5,502,402 shares of common stock for resale by Sermonix Pharmaceuticals, Inc., issuable upon exercise of a pre-funded warrant from a December 2025 licensing transaction. LeonaBio will not sell any shares in this offering and receives no resale proceeds.
The company will receive only the nominal cash exercise price of $0.001 per share, or about $5,502 in gross proceeds if the warrant is fully exercised. As of March 16, 2026, LeonaBio had 9,393,514 shares of common stock outstanding, and its stock traded at $8.42 per share on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. is registering up to 58,464,567 shares of common stock for resale by existing investors under a Form S-1 converted from a prior Form S-3. These shares include stock already issued and shares issuable from pre-funded warrants and other warrants held by December 2025 private placement investors.
LeonaBio will not sell any shares in this offering and will not receive proceeds from selling stockholders’ resales. It may receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share, and approximately $146,249,987 from cash exercises of warrants on 23,031,494 underlying shares at $6.35 per share. As of March 16, 2026, 9,393,514 shares of common stock were outstanding, and the stock traded at $8.42 on Nasdaq under the symbol LONA.
LeonaBio, Inc. reports its business overview and drug pipeline, highlighting two main programs: lasofoxifene for ESR1‑mutated metastatic breast cancer and ATH‑1105 for amyotrophic lateral sclerosis (ALS). The company in‑licensed global rights (excluding Asia and parts of the Middle East) to oral lasofoxifene from Sermonix and Ligand and is assuming responsibility for the ongoing Phase 3 ELAINE‑3 trial, which combines lasofoxifene with abemaciclib. Earlier Phase 2 data showed median progression‑free survival of 5.6 months for lasofoxifene versus 3.7 months for fulvestrant, and 13‑month median progression‑free survival for lasofoxifene plus abemaciclib in heavily pretreated patients. ATH‑1105 is an oral small molecule that positively modulates the neurotrophic HGF/MET system, with extensive preclinical ALS data showing neuroprotection, reduced inflammation and improved motor function, and a completed Phase 1 trial in healthy volunteers demonstrating favorable safety, dose‑proportional pharmacokinetics and CNS penetration. LeonaBio outlines plans for a Phase 2 ALS trial focused on neurofilament light chain as a biomarker and describes broad intellectual property coverage and third‑party manufacturing arrangements to support potential commercialization.
LeonaBio, Inc. filed a second amendment to an earlier report to align with SEC guidance treating its Sermonix transaction as an acquisition of a business. The company obtained a waiver from certain financial statement requirements in exchange for providing expanded qualitative and cash expenditure disclosures.
The amendment details historical unaudited cash spending on the ELAINE-3 Study, including about $14 million, $12 million and $5 million by Sermonix in 2023, 2024 and part of 2025, and approximately $11 million by LeonaBio from December 18 through December 31, 2025. LeonaBio now expects to spend about $45 million in 2026 and $30 million in 2027 as it broadens the study scope.
The company has increased the ELAINE-3 Study intensity, expanded the contract research organization’s responsibilities, and plans to raise the sample size from 500 to up to 600 participants. It currently expects to complete enrollment in the fourth quarter of 2026 and release topline data in the second half of 2027.